Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.60 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.57 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.56 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.49 |
| ▸ | AHR | P35869 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7169246 | 0.87 | LOXL2 (0.69) | LOXL2MTNR1AMTNR1BHRH3CHRNA7 | |
| SCHEMBL31059889 | 0.87 | LOXL2 (0.69) | LOXL2MTNR1AMTNR1BHRH3CHRNA7 | |
| SCHEMBL28335219 | 0.85 | LOXL2 (0.67) | LOXL2MTNR1AMTNR1BHRH3CHRNA7 | |
| SCHEMBL4958614 | 0.84 | LOXL2 (0.60) | LOXL2MTNR1AMTNR1BHRH3CHRNA7 | |
| SCHEMBL6165439 | 0.84 | LOXL2 (0.60) | LOXL2MTNR1AMTNR1BHRH3CHRNA7 | |
| SCHEMBL3022232 | 0.83 | LOXL2 (0.64) | LOXL2MTNR1AMTNR1BHRH3AHR | |
| SCHEMBL6860219 | 0.83 | LOXL2 (0.64) | LOXL2MTNR1AMTNR1BHRH3CHRNA7 | |
| SCHEMBL29403791 | 0.83 | LOXL2 (0.69) | LOXL2MTNR1AMTNR1BHRH3AHR | |
| SCHEMBL401081 | 0.83 | LOXL2 (0.69) | LOXL2MTNR1AMTNR1BHRH3AHR | |
| SCHEMBL28338445 | 0.83 | LOXL2 (0.69) | LOXL2MTNR1AMTNR1BHRH3AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115872930-A | N-substituted 3,4-dihydroisoquinoline-1 (2H) -ketone derivative, composition thereof and application thereof in medicines | 贵州医科大学 | 2023-03-31 | — | — | CN | claimed |
| US-9487494-B2 | Cyclic hydrocarbon compounds for the treatment of diseases | LEO PHARMA A/S (DK) | 2016-11-08 | — | — | US | claimed |
| US-20100317582-A1 | NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES | LEO PHARMA A/S (DK) | 2010-12-16 | — | — | US | claimed |
| EP-2234961-A2 | NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES | LEO PHARMA A/S (DK) | 2010-10-06 | — | — | EP | claimed |
| WO-2009065406-A2 | NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES | LEO PHARMA A/S (DK) | 2009-05-28 | — | — | WO | claimed |
| CN-115872930-A | N-substituted 3,4-dihydroisoquinoline-1 (2H) -ketone derivative, composition thereof and application thereof in medicines | 贵州医科大学 | 2023-03-31 | — | — | CN | disclosed |
| WO-2005025554-A2 | DIPEPTIDYL PEPTIDASE IV INHIBITOR | JAPAN TOBACCO INC. (JP) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317582-A1 | NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES | ARNT, AHR, CYP27A1 | LOXL2 1204/4885MTNR1A 80/4885MTNR1B 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.